Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
University of California, San Francisco
Telix Pharmaceuticals (Innovations) Pty Limited
Washington University School of Medicine
Hoffmann-La Roche
Baptist Health South Florida
Eastern Cooperative Oncology Group
Neonc Technologies, Inc.
OHSU Knight Cancer Institute
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
National Institutes of Health Clinical Center (CC)